Evidence map›Paper›PMID 26856702›Full record

ArticleGenome medicine2016

Exonic enhancers: proceed with caution in exome and genome sequencing studies.

Nadav Ahituv

Abstract read
In one paragraph

Article in Genome medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Promoter mutagenesis and a massively parallel reporter screen of thebioRxiv : the preprint server for biology · 2026
    Article
  9. Article
  10. Introducing the EpGEpigenomes · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Analysis of the landscape of human enhancer sequences in biological databases.Computational and structural biotechnology journal · 2022
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Nadav AhituvDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, 94158, USA. nadav.ahituv@ucsf.edu.

Funding

Integrative interpretation of the organismal consequences of non-coding variationR01CA197139 · NCI · UNIVERSITY OF WASHINGTON · PI COOPER, GREGORY MICHAEL, SHENDURE, JAY ASHOK · 2015 to 2017
$1.9M
Identification & functional characterization of SIM1 obesity-associated variantsR01DK090382 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AHITUV, NADAV, VAISSE, CHRISTIAN · 2012 to 2015
$1.3M
Characterization of neuronal gene regulatory elements associated with epilepsyR01NS079231 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AHITUV, NADAV · 2012 to 2015
$1.2M
NCI NIH HHS 1R01CA197139NCI NIH HHS R01 CA197139NIDDK NIH HHS 1R01DK090382NIDDK NIH HHS R01 DK090382NINDS NIH HHS 1R01NS079231NINDS NIH HHS R01 NS079231
6 · The paper itself

Abstract

Exonic enhancers (eExons) are coding exons that also function as enhancers of the gene in which they reside or (a) nearby gene(s). Mutations that affect the enhancer activity of these eExons have been associated with human disease. Therefore, eExon mutations should be taken into account in exome and genome sequencing projects, not only because of the ability of these mutations to modify the encoded proteins but also because of their effects on enhancer activity.

Indexed as

Enhancer Elements, GeneticExomeCytoplasmic DyneinsGenome, HumanHomeodomain ProteinsHumansMutationSequence Analysis, DNATranscription FactorsCytoplasmic DyneinsDLX5 protein, humanDLX6 protein, humanDYNC1I1 protein, humanHomeodomain ProteinsTranscription Factors

Identifiers

PMID26856702
PMCPMC4745165

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.